OmniAb: A $4 Million Quarter Riding a 117% Two-Week Melt-Up
xPloration finally gets a number, cash burn goes to roughly zero, and Lilly buys an ion channel — but the tape already paid for it
OABI · Earnings Call · 2026-10-30
A small quarter in a stock that just went vertical
On October 30, OmniAb reported third-quarter revenue of $4.0 million against $2.2 million a year earlier. That is not a number that moves a stock on its own. The tape did the moving first: the shares are up 103.6% over the last 90 days, including a two-week burst of roughly +117%, and closed the day of the call within 3.2% of a $5.28 high set on October 28. Strip out the euphoria and the longer arc is still ugly — a full-history return of -47.6% from an October 2022 peak of $10.31, even after a +250% run off the low of 25 weeks ago. This is a broken-chart company reporting into a brand-new high, with no news flow to explain the run.
So the question is not what the quarter printed. It is whether the quarter earned the move, or merely failed to contradict it.
The promise that finally got a number
For three quarters, xPloration — the AI-flavored, high-throughput single B-cell screening instrument — has been the company's most talked-about and least quantified asset. On the August call, the answer to "what can this generate?" was a deferral:
we're still evaluating the full commercial opportunity for xPloration and how best to capture that. And we'll aim to maybe share more of our thinking around that ... at our upcoming Analyst and Investor Day.
That Investor Day has now happened, and the deferral has converted into a forecast:
we expect xPloration revenue in 2026 to be between $2 million and $3 million, and we expect xPloration revenue to double in 2027 and to double again in 2028.
That is the single most important change in this report. xPloration revenue jumps to the top tier of the company's own keyword stack this quarter, alongside recurring revenue — language that did not exist in OmniAb's vocabulary a year ago, when the story was royalties, milestones and partner counts. Management is explicit that the shape is instrument-first: "most of our revenue today is coming from instruments placement," with consumables, software and service to follow. And to their credit, they did not oversell the pull-through: it is, in Amechi Nwachuku's words, “early days to be able to tell you that it has stabilized.” — Amechi Nwachuku, Executive or Senior Manager (likely in Commercial or Product Management) · 2026-10-30
The inconvenient mechanical detail is the sales cycle. “the pipeline for an instrument sale could be anywhere from 12 to 18 months,” — Matthew Foehr, Chief Executive Officer (CEO) · 2026-10-30 the CEO said — a capital-budget gauntlet that makes a doubling guide for 2027 an act of faith as much as a forecast, resting on a capital side conversation that started well before today.
From a $20 million hole to roughly breakeven
In August, the sharpest question on the call came from Rodman's Michael King, who noted the company faced a “$20-plus million gap between your spend and the expected revenues” — Michael King, Analyst · 2026-08-06. The CFO's answer then was that OmniAb was “burning about $15 million this year” — Kurt Gustafson, Chief Financial Officer · 2026-08-06. Three months later the same CFO is describing a different company:
“We started the year with $54 million in cash, which means from a net cash flow standpoint, we expect the business to be basically breakeven for the year.” — Kurt Gustafson, Chief Financial Officer (CFO) · 2026-10-30
Guidance went up on the top line — $35 million to $39 million from $32 million to $36 million — and down on cost, with operating expense trimmed $1 million and year-end cash now guided to $53–57 million. Year-to-date revenue of $31.8 million versus $10.3 million is doing most of that work, and it is milestone revenue, which is inherently lumpy: the top line grew 244% year over year in the last filed quarter in a pattern that saw $14 million in Q1, $13 million in Q2 and $4 million in Q3. Meanwhile the underlying cash machinery has genuinely improved, with free cash flow (less stock comp) recovering from roughly -$9 million in mid-2025 to about -$0.6 million in the most recent filing.
That is a real inflection. It is also the one thing management can control without a partner doing anything, which matters enormously for a company whose revenue depends on other people's clinical readouts.
The royalty engine still runs on other people's data
The licensor business did not stand still. Ion Channel is the company's top keyword this quarter on the back of the Eli Lilly deal — an upfront payment, up to $370 million in research, development and commercial milestones, and tiered royalties. Partner count is 111, active programs 433 (up from 407 at year-end), 34 clinical programs and approved products carrying roughly $340 million of remaining milestones, and more than $3 billion of total contracted potential milestones at an average royalty rate of about 3.4%.
The freshest catalyst is Batoclimab in China, approved for generalized myasthenia gravis and the fourth approved drug from the platform — though on the royalty line the CEO was candid: “still too early to know what pricing will be ... But I would just say stay tuned on that.” — Matthew Foehr, Chief Executive Officer (CEO) · 2026-10-30 A new peptide discovery offering, OmniTides, was launched off the OmniUltra transgenic chicken, aimed at metabolic-era peptide demand.
The tension: what got quieter, and what identity wins
Two things are worth flagging. First, IMVT-1402 — IMVT 1402, a top-three keyword for this company as recently as the June quarter — surfaced only in passing, as the CFO explained royalties become the biggest revenue line when that program “might start in late 2028” — Kurt Gustafson, Chief Financial Officer (CFO) · 2026-10-30. The visible late-stage anchor has been quietly subordinated to a breadth story about 34 programs. Second, the valuation vocabulary has shifted shape: price to revenue of 9.3x sits well below the 30.2x peak, yet the shares just doubled on an instrument narrative rather than a royalty one.
That is the story. OmniAb spent years asking investors to underwrite other companies' molecules through milestones and a 3.4% royalty. This quarter it began asking them to underwrite its own hardware and consumables — a far more controllable, far more scalable-sounding pitch, with larger partners and an installed base behind it. The data layers and AI framing are real but tangential to the tape: the AI themes driving the market's hottest and now-fading trades — data center capacity, co-packaged optics, high-bandwidth memory — are compute stories, and OmniAb sells biological data, not silicon.
The quarter earned an upgrade, not a doubling. Guidance up, cost down, cash flat, and a new revenue line with a number on it is exactly what a company at this stage should deliver. But with the stock at a fresh high, the burden has shifted to a 12-to-18-month capital sales cycle and a consumables ramp nobody can yet measure — and milestone revenue that arrives when partners, not OmniAb, decide it should.